Longitudinal Study of SARS-CoV-2 Vaccinations and Infections in Patients with Gastrointestinal Cancer: Stabilizing Immune Responses and Neutralizing Emerging Variants with Variant-Adapted Antigen Exposures
Authors:
- Maria A. Gonzalez-CarmonaMGMaria A. Gonzalez-Carmona
- Alina M. SchmitzASAlina M. Schmitz
- Moritz BergerMBMoritz Berger
- Leona I. BaierLBLeona I. Baier
- Jens G. GornyJGJens G. Gorny
- Farsaneh SadeghlarFSFarsaneh Sadeghlar
- Thomas AnhaltTAThomas Anhalt
- Xin ZhouXZXin Zhou
- Taotao ZhouTZTaotao Zhou
- Robert MahnRMRobert Mahn
- Christian MöhringCMChristian Möhring
- Thomas LinnemannTLThomas Linnemann
Open Access
- 19 December 2024
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (24) , 13613
Abstract
This longitudinal study examined how active gastrointestinal (GI) cancer types affect immune responses to SARS-CoV-2, focusing on the ability to neutralize the Omicron variants. Patients with GI cancer (n = 168) were categorized into those with hepatocellular carcinoma, hepatic metastatic GI cancer, non-hepatic metastatic GI cancer, and two control groups of patients with and without underlying liver diseases. Humoral and cellular immune responses were evaluated before and after Omicron antigen exposures. In the pre-Omicron era, humoral SARS-CoV-2 immunity decreased after three antigen contacts without further antigen exposure. While Omicron neutralization was significantly lower than wildtype neutralization (p < 0.01), Omicron infections were yet mild to moderate. Additional Omicron exposures improved IgG levels (p < 0.01) and Omicron neutralization (p < 0.01). However, this effect was significantly less intense in patients with active GI cancer, particularly in patients with pancreaticobiliary neoplasms (PBN; p = 0.04), with underlying immunodeficiency (p = 0.05), and/or under conventional chemotherapy (p = 0.05). Pre-Omicron SARS-CoV-2 immunity prevented severe clinical courses of infections with Omicron variants in patients with GI cancer. However, in patients with PBN, with underlying immunodeficiency, and/or under conventional chemotherapy initial contacts with Omicron antigens triggered only reduced immune responses. Thus, subgroups could be identified for whom booster vaccinations are of special clinical significance.Keywords
This publication has 52 references indexed in Scilit:
- Early combination therapy of COVID-19 in high-risk patientsInfection, 2023
- Antiviral treatment of COVID-19: which role can clinical parameters play in therapy evaluation?Infection, 2023
- Longitudinal data on humoral response and neutralizing antibodies against SARS-CoV-2 Omicron BA.1 and subvariants BA.4/5 and BQ.1.1 after COVID-19 vaccination in cancer patientsJournal of Cancer Research and Clinical Oncology, 2023
- Live‐virus neutralization of the omicron variant in children and adults 14 months after SARS‐CoV‐2 wild‐type infectionJournal of Medical Virology, 2023
- Use and effectiveness of remdesivir for the treatment of patients with covid-19 using data from the Lean European Open Survey on SARS-CoV-2 infected patients (LEOSS): a multicentre cohort studyInfection, 2023
- Declining COVID-19 morbidity and case fatality in Germany: the pandemic end?Infection, 2022
- Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serumCell, 2022
- WHO Ordinal Scale and Inflammation Risk Categories in COVID-19. Comparative Study of the Severity ScalesJournal of General Internal Medicine, 2022
- SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to OmicronCell, 2022
- The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemicCell, 2021